Beyond the blood report: Why India’s next healthcare revolution isn’t about data, but meaning

Something significant is happening in Indian healthcare, and it deserves more attention than it is getting. A decade ago, preventive health check-ups were the habit of a small, urban minority. Today, they are becoming mainstream. India’s health check-up market, valued at $1.7 billion in 2024, is projected to reach $3.1 billion by 2033. People in their twenties and thirties are booking full-body health packages without waiting for symptoms. The ABDM has linked over 110 crore digital health records to more than 96 crore ABHA accounts, an infrastructure achievement no other country has attempted at this scale. Wearables are adding a continuous data layer on top. India is, by almost any measure, becoming a nation that takes its health data seriously.

This is genuinely exciting. And it sets up the most important question Indian healthcare needs to answer next. What are we doing with all of it?

A health record tells you what was measured on a particular day. It does not tell you what is changing, why it is changing, or what the body has been trying to signal all along. A person can have a report that sits comfortably within normal ranges and still be dealing with persistent fatigue, poor sleep, unexplained changes in weight, or a digestive system that has never quite worked the way it should. The report says fine. The person does not feel fine.

This is not a failure of diagnostics. It is a limitation of the question diagnostics was designed to answer. The question has always been: how bad is it? The question we need to start asking is: why is it there at all? That shift, from measuring the condition to understanding its cause, is where the next wave of Indian healthcare will be built. The infrastructure for measurement is now in place. The next step is the infrastructure for interpretation.

The data that makes this urgent is hard to ignore. India has 101 million people living with diabetes and 315 million with hypertension, according to the ICMR-INDIAB study, one of the largest nationally representative health surveys conducted in India. NCDs now account for nearly 70 per cent of all deaths in the country. And yet, despite the proliferation of testing and digital health records, the trajectory of these conditions continues to climb. More data has not translated into better outcomes. That gap is not a coincidence. It is a signal.

Medicine is getting better at finding things earlier. Screening tools are improving. AI-assisted diagnostics are catching patterns that human review would miss. Biomarker research is advancing to a point where signals of disease can be detected years before symptoms appear, as demonstrated recently by Oxford Population Health’s research detecting cancer-associated DNA changes 5 to 8 years before diagnosis, and AI-enhanced liquid biopsies showing high accuracy in detecting early-stage pancreatic cancer. These are genuine breakthroughs representing some of the most promising work happening in healthcare globally. But early detection creates an obligation.

If we can identify a signal years before it becomes a diagnosis, the question becomes what we do with that time. An alert without a clinical pathway for addressing what is driving it is not a solution, it is an earlier warning with the same ending. The value of finding something early is only fully realised when the system knows what to do next. Detection and interpretation need to move together. Right now, the first is accelerating faster than the second.

The pharmaceutical industry has delivered genuine breakthroughs too. But a drug that produces results while you are on it and returns the problem when you stop it has not solved the problem, it has deferred it. The question is not whether a given intervention works. The question is what comes before it, and what comes alongside it. What is the underlying disruption that made the intervention necessary? Has anything been done to address that upstream driver? The goal should be progressively less dependence on medication over time, not lifelong management by default.

India is on the right trajectory. The investment in digital health infrastructure, the cultural shift toward preventive testing, the acceleration of diagnostics technology, all of it is moving in the right direction. The next step is not more data. It is better questions. Not just what the report says, but what the report means. Not just what condition someone has, but what produced it, and what addressing that cause might change.

For decades, the central question in Indian healthcare has been: how do we get more people tested? That question has largely been answered. Infrastructure exists. Access is expanding. Data is accumulating at a pace that would have seemed impossible ten years ago. The question that follows is harder and more important: now that we have the data, are we asking the right things? Now that we have abundant data, the next step is to fully understand that data to go beyond the surface-level diagnosis, find out downstream factors responsible for current symptoms, and identify the indicators that could trigger future health issues.

The measurement revolution in Indian healthcare has arrived. The interpretation revolution is what follows. And that is where the most important work of the next decade will happen.